Skip to main
AVDL
AVDL

Avadel Pharma (AVDL) Stock Forecast & Price Target

Avadel Pharma (AVDL) Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 69%
Buy 31%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avadel Pharmaceuticals PLC demonstrates a positive outlook driven by its innovative product, LUMRYZ, which is anticipated to generate over $500 million in peak sales due to its once-nightly dosing convenience compared to other sodium oxybates. The company's management has maintained financial guidance, projecting a year-over-year sales increase to $240-$260 million by year-end 2025, with patient counts expected to rise by 40%. Furthermore, favorable trends in patient enrollments and the potential for expansion into new therapeutic indications suggest robust growth opportunities ahead.

Bears say

Avadel Pharmaceuticals faces a challenging outlook due to anticipated declines in LUMRYZ sales, with projected first-quarter figures indicating a muted performance influenced by seasonal dynamics and insurance re-authorizations. The company's value proposition in the narcolepsy treatment market may not meet sales expectations, further compounding concerns regarding its ability to compete effectively with larger competitor Jazz Pharmaceuticals. Additionally, the potential for underperformance in sales growth raises questions about the company's valuation and the market's perception of its financial prospects moving forward.

Avadel Pharma (AVDL) has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 69% of analysts recommend a Strong Buy, 31% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avadel Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avadel Pharma (AVDL) Forecast

Analysts have given Avadel Pharma (AVDL) a Strong Buy based on their latest research and market trends.

According to 13 analysts, Avadel Pharma (AVDL) has a Strong Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avadel Pharma (AVDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.